Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Puma Biotechnology, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

08/05/2021 | 04:17pm EDT

Puma Biotechnology, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 53.4 million compared to USD 70.6 million a year ago. Operating loss was USD 16.6 million compared to operating Income of USD 7.1 million a year ago. Net loss was USD 5.1 million compared to net income of USD 3.4 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to basic earnings per share from continuing operations of USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.13 compared to diluted earnings per share from continuing operations of USD 0.08 a year ago. For the half year, total revenue was USD 151.6 million compared to USD 121.8 million a year ago. Operating income was USD 3.5 million compared to operating loss of USD 7.1 million a year ago. Net income was USD 11.3 million compared to net loss of USD 13.5 million a year ago. Basic earnings per share from continuing operations was USD 0.28 compared to basic loss per share from continuing operations of USD 0.34 a year ago.


© S&P Capital IQ 2021
All news about PUMA BIOTECHNOLOGY, INC.
10/06PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
09/28PUMA BIOTECHNOLOGY : Citigroup Upgrades Puma Biotechnology to Buy From Neutral, Price Targ..
MT
09/21PUMA BIOTECHNOLOGY : to Present at the Cantor Virtual Global Healthcare Conference
BU
09/20PUMA BIOTECHNOLOGY, INC.(NASDAQGS : PBYI) dropped from S&P Biotechnology Select Industry I..
CI
09/07PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
09/07PUMA BIOTECHNOLOGY : to Present at the H.C. Wainwright 23rd Annual Global Investment Confe..
BU
08/06PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
08/06PUMA BIOTECHNOLOGY : RBC Cuts PT on Puma Biotechnology to $6 From $13, Citing Nerlynx 2021..
MT
08/05PUMA BIOTECH : Q2 Earnings Snapshot
AQ
08/05PUMA BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
More news
Analyst Recommendations on PUMA BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 266 M - -
Net income 2021 -1,69 M - -
Net cash 2021 54,4 M - -
P/E ratio 2021 -24,4x
Yield 2021 -
Capitalization 247 M 247 M -
EV / Sales 2021 0,72x
EV / Sales 2022 0,74x
Nbr of Employees 267
Free-Float 86,6%
Chart PUMA BIOTECHNOLOGY, INC.
Duration : Period :
Puma Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PUMA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 6,05 $
Average target price 8,63 $
Spread / Average Target 42,6%
EPS Revisions
Managers and Directors
Alan H. Auerbach Chairman, President, CEO & Secretary
Maximo F. Nougues Chief Financial Officer
Jay M. Moyes Lead Independent Director
Troy E. Wilson Independent Director
Adrian M. Senderowicz Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PUMA BIOTECHNOLOGY, INC.-41.03%247
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414